BR112021006898A2 - nova solução de combinação para tratar câncer refratário à quimioterapia - Google Patents

nova solução de combinação para tratar câncer refratário à quimioterapia Download PDF

Info

Publication number
BR112021006898A2
BR112021006898A2 BR112021006898-8A BR112021006898A BR112021006898A2 BR 112021006898 A2 BR112021006898 A2 BR 112021006898A2 BR 112021006898 A BR112021006898 A BR 112021006898A BR 112021006898 A2 BR112021006898 A2 BR 112021006898A2
Authority
BR
Brazil
Prior art keywords
cancer
pharmaceutically acceptable
solvates
acceptable salts
compound
Prior art date
Application number
BR112021006898-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Chiang J. Li
Original Assignee
1Globe Biomedical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co., Ltd. filed Critical 1Globe Biomedical Co., Ltd.
Publication of BR112021006898A2 publication Critical patent/BR112021006898A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021006898-8A 2018-10-12 2019-10-12 nova solução de combinação para tratar câncer refratário à quimioterapia BR112021006898A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811195239.3 2018-10-12
CN201811195239 2018-10-12
PCT/CN2019/110904 WO2020074010A1 (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案

Publications (1)

Publication Number Publication Date
BR112021006898A2 true BR112021006898A2 (pt) 2021-07-20

Family

ID=70163618

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021006898-8A BR112021006898A2 (pt) 2018-10-12 2019-10-12 nova solução de combinação para tratar câncer refratário à quimioterapia

Country Status (15)

Country Link
US (2) US12257227B2 (https=)
EP (1) EP3865130A4 (https=)
JP (2) JP7513286B2 (https=)
CN (2) CN120168498A (https=)
AU (1) AU2019357933B2 (https=)
BR (1) BR112021006898A2 (https=)
CA (1) CA3115869A1 (https=)
EA (1) EA202190771A1 (https=)
IL (1) IL282228A (https=)
MX (1) MX2021004151A (https=)
PH (1) PH12021550815A1 (https=)
SG (1) SG11202103707TA (https=)
TW (1) TWI848990B (https=)
WO (1) WO2020074010A1 (https=)
ZA (1) ZA202102494B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865130A4 (en) * 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050566B1 (en) 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
EP2547205B1 (en) 2010-03-19 2024-03-20 1Globe Biomedical Co., Ltd. Novel methods for targeting cancer stem cells
RU2571661C2 (ru) 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
EP2983790A2 (en) * 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
US20180085341A1 (en) 2015-04-17 2018-03-29 Boston Biomedical, Inc. Methods for treating cancer
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
CN107766371B (zh) * 2016-08-19 2023-11-17 中兴通讯股份有限公司 一种文本信息分类方法及其装置
EP3865130A4 (en) * 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER

Also Published As

Publication number Publication date
CN120168498A (zh) 2025-06-20
US20250235425A1 (en) 2025-07-24
CN113164438B (zh) 2025-03-18
PH12021550815A1 (en) 2021-10-04
JP7513286B2 (ja) 2024-07-09
JP2024123152A (ja) 2024-09-10
JP2022504760A (ja) 2022-01-13
AU2019357933A1 (en) 2021-05-20
EP3865130A1 (en) 2021-08-18
MX2021004151A (es) 2021-09-08
EA202190771A1 (ru) 2021-09-07
CA3115869A1 (en) 2020-04-16
EP3865130A4 (en) 2022-07-20
IL282228A (en) 2021-05-31
SG11202103707TA (en) 2021-05-28
AU2019357933B2 (en) 2023-11-23
US12257227B2 (en) 2025-03-25
US20210393571A1 (en) 2021-12-23
TW202027738A (zh) 2020-08-01
KR20210076951A (ko) 2021-06-24
TWI848990B (zh) 2024-07-21
WO2020074010A1 (zh) 2020-04-16
ZA202102494B (en) 2023-01-25
CN113164438A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
US20190224157A1 (en) Methods for treating cancer
US20180085341A1 (en) Methods for treating cancer
US10646464B2 (en) Methods for treating cancer
US20190231735A1 (en) Methods for treating cancer
US20180250261A1 (en) Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
US20250235425A1 (en) New Combination Solution for Treating Chemotherapy Refractory Cancer
US20180098959A1 (en) Methods for treating cancer
KR102960038B1 (ko) 화학요법 불응성 암을 치료하기 위한 신규한 조합 방안
HK40048413A (en) New combination solution for treating chemotherapy refractory cancer
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии
HK40047114A (en) New combination solution for treating chemotherapy refractory cancer
HK40124738A (zh) 治疗化疗难治性癌症的新联合用药方案

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]